Estradiol cypionate /
testosterone cypionate
Estradiol cypionate (top) and
testosterone cypionate (bottom)
Combination of
Estradiol cypionateEstrogen
Testosterone cypionateAndrogen; Anabolic steroid
Clinical data
Trade namesDepo-Testadiol, Femovirin, depAndrogyn, others
Other namesEC/TC
Routes of
administration		Intramuscular injection
Identifiers
CAS Number

Estradiol cypionate/testosterone cypionate (EC/TC), sold under the brand names Depo-Testadiol and Femovirin among others, is an injectable combination medication of estradiol cypionate (EC), an estrogen, and testosterone cypionate (TC), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women.[1] It is specifically indicated for the treatment of moderate-to-severe vasomotor symptoms (i.e., hot flashes), but can also be used for other estrogen indications in women.[1] The medication has also been used to suppress lactation in postpartum women.[2]

Depo-Testadiol was provided in the form of 10 mL vials containing 2 mg/mL EC and 50 mg/mL TC in an oil solution and was administered by intramuscular injection once every 4 weeks.[1] Conversely, Femovirin was provided in the form of 1 mL ampoules containing 3.5 mg/mL EC (2.4 mg/mL free estradiol) and 90 mg/mL TC (62.9 mg/mL free testosterone) in an oil solution and was administered by intramuscular injection once every 4 to 6 weeks.[3]

[4][5][6][7] The elimination half-life of EC in oil by intramuscular injection is approximately 5 days, while the elimination half-life of TC in oil by intramuscular injection is approximately 8 days.[1] EC/TP reportedly has a duration of about 21 days.[8]

EC/TC likely poses a considerably increased risk of endometrial hyperplasia and cancer in women with intact uteruses (i.e., women who are not hysterectomized) if it is not combined with a progestogen.[1] This is due to the EC component.[1] The concomitant use of a progestogen will abolish such risks.[1] The medication can also cause masculinization, such as acne, deepened voice, hirsutism, and increased sex drive, due to its TC component.[1] Some of these masculinizing symptoms, such as voice deepening, can be irreversible.[1]

Depo-Testadiol was introduced for medical use in 1954,[9] while Femovirin was introduced for medical use in 1956.[10] An oral tablet product with the same brand name of Femovirin, containing ethinylestradiol and methyltestosterone, was marketed in 1958, and should not be confused with the injectable Femovirin.[11][4] Depo-Testadiol was discontinued in the United States by 2013.[12] Both Depo-Testadiol and Femovirin have been discontinued in most other countries, but formulations of EC/TC under other brand names continue to be marketed in Taiwan.[13][14][15]

Androgen replacement therapy formulations and dosages used in women
RouteMedicationMajor brand namesFormDosage
OralTestosterone undecanoateAndriol, JatenzoCapsule40–80 mg 1x/1–2 days
MethyltestosteroneMetandren, EstratestTablet0.5–10 mg/day
FluoxymesteroneHalotestinTablet1–2.5 mg 1x/1–2 days
NormethandroneaGinecosideTablet5 mg/day
TiboloneLivialTablet1.25–2.5 mg/day
Prasterone (DHEA)b–Tablet10–100 mg/day
SublingualMethyltestosteroneMetandrenTablet0.25 mg/day
TransdermalTestosteroneIntrinsaPatch150–300 μg/day
AndroGelGel, cream1–10 mg/day
VaginalPrasterone (DHEA)IntrarosaInsert6.5 mg/day
InjectionTestosterone propionateaTestovironOil solution25 mg 1x/1–2 weeks
Testosterone enanthateDelatestryl, Primodian DepotOil solution25–100 mg 1x/4–6 weeks
Testosterone cypionateDepo-Testosterone, Depo-TestadiolOil solution25–100 mg 1x/4–6 weeks
Testosterone isobutyrateaFemandren M, FolivirinAqueous suspension25–50 mg 1x/4–6 weeks
Mixed testosterone estersClimacteronaOil solution150 mg 1x/4–8 weeks
Omnadren, SustanonOil solution50–100 mg 1x/4–6 weeks
Nandrolone decanoateDeca-DurabolinOil solution25–50 mg 1x/6–12 weeks
Prasterone enanthateaGynodian DepotOil solution200 mg 1x/4–6 weeks
ImplantTestosteroneTestopelPellet50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

See also

References

  1. 1 2 3 4 5 6 7 8 9 "Depo-Testadiol® testosterone cypionate– estradiol cypionate injection". CiteSeerX 10.1.1.703.5708.
  2. ↑ Vorherr H (July 1972). "Suppression of postpartum lactation". Postgraduate Medicine. 52 (1): 145–152. doi:10.1080/00325481.1972.11713186. PMID 5037562.
  3. ↑ Kuhlencordt F, Rausch-Stroomann JG (1959). "Stoffwechsel-Bilanz untersuchungen un Hormontherapie bei verschiedenen Formen der Osteoporose". In Kauffmann F (ed.). Fünfundsechzigster Kongress: Gehalten zu Wiesbaden vom 6.–9. April 1959. Springer-Verlag. pp. 162–166. ISBN 978-3-642-96026-0.
  4. 1 2 Hager HH, Kern W, List PH, Roth HJ (29 July 2013). "Hormone". Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 156, 185. ISBN 978-3-662-25655-8.
  5. ↑ Saure A (11 November 2013). "Hormonpräparate, die zur Behandlung der Wechseljahre eingesetzt werden". Die Wechseljahre der Frau: Hormone — Präparate — Therapien. Springer-Verlag. pp. 157–. ISBN 978-3-0348-6676-7.
  6. ↑ Arends G, Zörnig H, Hager H, Frerichs G, Kern W (14 December 2013). "Hormone". Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte. Springer-Verlag. pp. 1164–. ISBN 978-3-662-36329-4.
  7. ↑ Kaiser R (2 July 2013). "Ovar". In Buchborn E, Jahrmärker H, Karl HJ, Martini GA, Müller W, Riecker G, Schwiegk H, Siegenthaler W, Stich W (eds.). Therapie innerer Krankheiten. Springer-Verlag. pp. 405–. ISBN 978-3-662-10489-7.
  8. ↑ Ufer J (1 January 1978). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis [Hormone Therapy in Gynecology: Principles and Practice] (in German) (5th ed.). de Gruyter. p. 276. ISBN 978-3110066647. OCLC 924728827.
  9. ↑ "NEW Prescription Products". Journal of the American Pharmaceutical Association (Practical Pharmacy Ed.). 16 (3): 193–200. 1955. doi:10.1016/S0095-9561(16)33664-7. ISSN 0095-9561.
  10. ↑ "Neue Spezialitäten". Klinische Wochenschrift. 34 (29–30): 819. 1956. doi:10.1007/BF01468058. ISSN 0023-2173. S2CID 33495393.
  11. ↑ "Neue Spezialitäten". Klinische Wochenschrift. 36 (24): 1169. 1958. doi:10.1007/BF01481649. ISSN 0023-2173. S2CID 12815948.
  12. ↑ Food and Drug Administration (2013). "Approved Drug Products with Therapeutic Equivalence Evaluations". FDA Orange Book (33rd ed.). Logos Press. pp. 619–. ISBN 978-1-934899-83-0.
  13. ↑ "Estradiol". Drugs.com.
  14. ↑ Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2100, 2124–2125. ISBN 978-0-85369-840-1.
  15. ↑ "IBM Watson Health Products: Please Login". www.micromedexsolutions.com.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.